These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 19140571)

  • 1. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
    Piatkowska-Jakubas B; Krawczyk-Kuliś M; Giebel S; Adamczyk-Cioch M; Czyz A; Lech Marańda E; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
    Pol Arch Med Wewn; 2008 Nov; 118(11):664-9. PubMed ID: 19140571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
    Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of L-asparaginase in childhood ALL.
    Müller HJ; Boos J
    Crit Rev Oncol Hematol; 1998 Aug; 28(2):97-113. PubMed ID: 9768345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia].
    Thomas X; Cannas G; Chelghoum Y; Gougounon A
    Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid asparagine depletion during pegylated asparaginase therapy in children with acute lymphoblastic leukaemia.
    Henriksen LT; Nersting J; Raja RA; Frandsen TL; Rosthøj S; Schrøder H; Albertsen BK;
    Br J Haematol; 2014 Jul; 166(2):213-20. PubMed ID: 24702187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia.
    Earl M
    Clin Adv Hematol Oncol; 2009 Sep; 7(9):600-6. PubMed ID: 20020672
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia.
    Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI
    Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
    Beinart G; Damon L
    Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse: a Children's Oncology Group study (CCG-1941).
    Jarrar M; Gaynon PS; Periclou AP; Fu C; Harris RE; Stram D; Altman A; Bostrom B; Breneman J; Steele D; Trigg M; Zipf T; Avramis VI
    Pediatr Blood Cancer; 2006 Aug; 47(2):141-6. PubMed ID: 16425271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An isocratic fluorescence HPLC assay for the monitoring of l-asparaginase activity and l-asparagine depletion in children receiving E. colil-asparaginase for the treatment of acute lymphoblastic leukaemia.
    Nath CE; Dallapozza L; Eslick AE; Misra A; Carr D; Earl JW
    Biomed Chromatogr; 2009 Feb; 23(2):152-9. PubMed ID: 18823071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
    Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
    Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
    Farrell K; Fyfe A; Allan J; Tait RC; Leach M
    Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-asparaginase: an effective agent in the treatment of acute lymphoblastic leukemia.
    Kumar K; Kaur J; Walia S; Pathak T; Aggarwal D
    Leuk Lymphoma; 2014 Feb; 55(2):256-62. PubMed ID: 23662993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The coagulopathy and thrombotic risk associated with L-asparaginase treatment in adults with acute lymphoblastic leukaemia.
    Truelove E; Fielding AK; Hunt BJ
    Leukemia; 2013 Mar; 27(3):553-9. PubMed ID: 23099335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
    Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
    Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. No evidence of increased asparagine levels in the bone marrow of patients with acute lymphoblastic leukemia during asparaginase therapy.
    Tong WH; Pieters R; Hop WC; Lanvers-Kaminsky C; Boos J; van der Sluis IM
    Pediatr Blood Cancer; 2013 Feb; 60(2):258-61. PubMed ID: 22961784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations.
    Boos J; Werber G; Ahlke E; Schulze-Westhoff P; Nowak-Göttl U; Würthwein G; Verspohl EJ; Ritter J; Jürgens H
    Eur J Cancer; 1996 Aug; 32A(9):1544-50. PubMed ID: 8911116
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Update on L-asparaginase treatment in paediatrics].
    Moscardó Guilleme C; Fernández Delgado R; Sevilla Navarro J; Astigarraga Aguirre I; Rives Solà S; Sánchez de Toledo Codina J; Fuster Soler JL; Parra Ramirez L; Molina Garicaño J; González Martínez B; Madero López L
    An Pediatr (Barc); 2013 Nov; 79(5):329.e1-329.e11. PubMed ID: 23727426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.